Summary
DON (6-diazo-5-oxo-l-norleucine) and azotomycin are glutamine antagonists that were tested in human malignancies in the 1950s. Azotomycin demonstrated significant activity in colorectal cancer. DON is probably the active form of azotomycin. Recent impressive results for both of these agents in human tumor xenografts (especially the CX-2 colon tumor) have stimulated renewed clinical interest in DON, the more readily available agent. DON mechanism of action, clinical pharmacology, previous clinical data, and current phase I studies are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Catane R, Ovejera AA, Houchens DP, Von Hoff DD, Davis HL Jr, Wolpert MK, Rozencweig M, Muggia FM (1978) Rationale for further clinical trials with 6-dia- zo-5-oxo-L-norleucine (DON) (abstr). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 19:317
Cooney DA, Jayaram HN, Milman HA, Homan ER, Pittillo R, Geran RI, Ryan J, Rosenbluth RJ (1976) DON, CONV and DONV-III, pharmacologic and toxicologic studies. Biochem Pharmacol 25:1859–1870
Hill GJ, Larsen RR, Sas EM (1973) Cancer chemotherapy II. Results of 603 courses of therapy in 400 consecutive patients followed for 18-52 months. Oncology 27:137–152
Li MC (1961) Management of chariocarcinoma and related tumors of the uterus and testis. Med Clin North Am 45:661–676
Livingston RB, Vendetti JM, Cooney DA, Carter SK (1970) Glutamine antagonists in chemotherapy, vol 8. Academic, New York, pp 62–83
Magill GB, Myers WPL, Reilly HC, Putnam RC, Magill JW, Sykes MP, Escher GC, Karnofsky GC, Burchenal JH (1957) Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-L-norleucine (DON) in human neoplastic disease. Cancer 10:1138–1150
Moore E, Hulbert R (1961) Biosynthesis of RNA cytosine and RNA purines; differential inhibition by 6-diazo-5-oxo-L-norleucine. Cancer Res 21:257–261
Moore EC, LePage GA (1957) In vivo sensitivity of normal and neoplastic mouse tissues to azaserine. Cancer Res 17:804–808
Ovejera AA, Houchens DP, Barker AD (1977) Chemotherapeutic sensitivity to anticancer agents of human tumor xenografts in athymic mice. Current Chemotherapy: Proc. 10th International Congress on Chemotherapy 2:1144–1146
Pittillo RF, Wooley C, Brockman RW, Ho DH (1971) Azotomycin (NSC-1566454): Biologic fate in mice and man. Cancer Chemother Rep 55:47–52
Prusiner S, Stadtman ER (eds) (1973) The enzymes of glutamine metabolism. Academic, New York
Rosenbluth RJ, Cooney DA, Jayaram HN, Milman HA, Homan ER (1976) DON, CONV, and DONV.-II, inhibition of L-asparaginase synthetase in vivo. Biochem Pharmacol 25:1851–1858
Veterans Administration Cancer Chemotherapy Study Group (1959) A clinical study of the comparative effect of nitrogen mustard and DON in patients with bronchogenic carcinoma, Hodgkin’s disease, lymphosarcoma and melanoma. J Natl Cancer Inst 22:433–439
Weiss AJ, Mastrangelo MJ (1970) Phase I study of a combination of azotomycin + 5-FU in malignant disease. Cancer Chemother Rep 54:109–111
Weiss AJ, Ramirez G, Grage T, Strawitz J, Goldman L, Downing V (1968) Phase II study of azotomycin. Cancer Chemother Rep 52:611–614
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kisner, D.L., Catane, R., Muggia, F.M. (1980). The Rediscovery of DON (6-Diazo-5-oxo-L-norleucine). In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_30
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive